Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663.

van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr.

Br J Pharmacol. 2000 Apr;129(8):1748-54.

2.

Disparate effects of thrombin receptor activating peptide on platelets and peripheral vasculature in rats.

Chintala MS, Chiu PJ, Bernadino V, Tetzloff GG, Tedesco R, Sabin C, Watkins RW, Sybertz EJ.

Eur J Pharmacol. 1998 May 22;349(2-3):237-43.

PMID:
9671103
3.

Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats.

Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, Van Heek M.

Obes Res. 1998 Mar;6(2):147-56.

4.

In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr.

J Pharmacol Exp Ther. 1997 Oct;283(1):157-63.

PMID:
9336320
5.

Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor, in guinea pigs.

Chiu PJ, Vemulapalli S, Chintala M, Kurowski S, Tetzloff GG, Brown AD, Sybertz EJ.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Apr;355(4):463-9.

PMID:
9109362
6.

Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs.

Chiu PJ, Tetzloff GG, Foster C, Chintala M, Sybertz EJ.

Eur J Pharmacol. 1997 Feb 19;321(1):129-35.

PMID:
9083795
7.

Diet-induced obese mice develop peripheral, but not central, resistance to leptin.

Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr.

J Clin Invest. 1997 Feb 1;99(3):385-90.

8.

The relationship of tissue localization, distribution and turnover to feeding after intraperitoneal 125I-leptin administration to ob/ob and db/db mice.

Van Heek M, Mullins DE, Wirth MA, Graziano MP, Fawzi AB, Compton DS, France CF, Hoos LM, Casale RL, Sybertz EJ, Strader CD, Davis HR Jr.

Horm Metab Res. 1996 Dec;28(12):653-8.

PMID:
9013736
9.

Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.

Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M, Lin CC, Sybertz EJ.

J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.

PMID:
8961086
10.

Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep.

Charles CJ, Espiner EA, Richards AM, Sybertz EJ.

Hypertension. 1995 Jul;26(1):89-94.

PMID:
7607738
11.

Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives.

Neustadt BR, Smith EM, Nechuta TL, Bronnenkant AA, Haslanger MF, Watkins RW, Foster CJ, Sybertz EJ.

J Med Chem. 1994 Jul 22;37(15):2461-76.

PMID:
8057292
12.

Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats.

Vemulapalli S, Chiu PJ, Griscti K, Brown A, Kurowski S, Sybertz EJ.

Eur J Pharmacol. 1994 May 12;257(1-2):95-102.

PMID:
8082712
13.

Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats.

Chintala MS, Chiu PJ, Vemulapalli S, Watkins RW, Sybertz EJ.

Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):305-10.

PMID:
8232607
14.

Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor.

Watkins RW, Vemulapalli S, Chiu PJ, Foster C, Smith EM, Neustadt B, Haslanger M, Sybertz EJ.

Am J Hypertens. 1993 May;6(5 Pt 1):357-68.

PMID:
8512660
15.

Sympathoadrenal stimulation, not endothelin, plays a role in acute pressor response to cyclosporine in anesthetized rats.

Chiu PJ, Vemulapalli S, Sabin C, Rivelli M, Bernardino V, Sybertz EJ.

J Pharmacol Exp Ther. 1992 Jun;261(3):994-9.

PMID:
1602404
17.

Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels.

Ahn HS, Crim W, Pitts B, Sybertz EJ.

Adv Second Messenger Phosphoprotein Res. 1992;25:271-88. Review. No abstract available.

PMID:
1313262
18.

Modulation of circulating endothelin levels in hypertension and endotoxemia in rats.

Vemulapalli S, Chiu PJ, Rivelli M, Foster CJ, Sybertz EJ.

J Cardiovasc Pharmacol. 1991 Dec;18(6):895-903.

PMID:
1725904
19.

Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.

Sybertz EJ Jr, Chiu PJ, Watkins RW, Vemulapalli S.

Can J Physiol Pharmacol. 1991 Oct;69(10):1628-35.

PMID:
1838029
20.
21.

Prolonged neutral endopeptidase inhibition in heart failure.

Helin K, Tikkanen I, Tikkanen T, Saijonmaa O, Sybertz EJ, Vemulapalli S, Sariola H, Fyhrquist F.

Eur J Pharmacol. 1991 May 30;198(1):23-30.

PMID:
1655477
22.

Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep.

Charles CJ, Espiner EA, Cameron VA, Richards AM, Yandle TG, Sybertz EJ.

Hypertension. 1991 May;17(5):643-51.

PMID:
1850715
23.

Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats.

Chiu PJ, Tetzloff G, Romano MT, Foster CJ, Sybertz EJ.

Am J Physiol. 1991 Jan;260(1 Pt 2):R208-16.

PMID:
1847022
24.

Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues.

Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ.

Adv Exp Med Biol. 1991;308:191-7. No abstract available.

PMID:
1666264
25.
26.

The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.

Vemulapalli S, Chiu PJ, Brown A, Griscti K, Sybertz EJ.

Life Sci. 1991;49(5):383-91. Erratum in: Life Sci 1992;50(12):899.

PMID:
1649942
27.

Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation.

Sybertz EJ Jr, Chiu PJ, Watkins RW, Vemulapalli S.

J Hypertens Suppl. 1990 Dec;8(7):S161-7.

PMID:
2151333
28.

Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor.

Tikkanen I, Helin K, Tikkanen T, Sybertz EJ, Vemulapalli S, Sariola H, Näveri H, Fyhrquist F.

J Pharmacol Exp Ther. 1990 Aug;254(2):641-5.

PMID:
2143536
29.

Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.

Sybertz EJ, Chiu PJ, Vemulapalli S, Watkins R, Haslanger MF.

Hypertension. 1990 Feb;15(2):152-61.

PMID:
2154404
30.

Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.

Watkins RW, Sybertz EJ, Cook J, Pula K, Cedeno K, Tedesco RP, McLeod R.

Arch Int Pharmacodyn Ther. 1989 Nov-Dec;302:158-73.

PMID:
2576892
31.

SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.

Sybertz EJ, Chiu PJ, Vemulapalli S, Pitts B, Foster CJ, Watkins RW, Barnett A, Haslanger MF.

J Pharmacol Exp Ther. 1989 Aug;250(2):624-31.

PMID:
2547941
32.

Angiotensin converting enzyme inhibitors: spirapril and related compounds.

Smith EM, Swiss GF, Neustadt BR, McNamara P, Gold EH, Sybertz EJ, Baum T.

J Med Chem. 1989 Jul;32(7):1600-6.

PMID:
2544729
34.

Phorbol dibutyrate inhibits release and action of endothelium-derived relaxing factor(s) in canine blood vessels.

Rubanyi GM, Desiderio D, Luisi A, Johns A, Sybertz EJ.

J Pharmacol Exp Ther. 1989 Jun;249(3):858-63.

PMID:
2499677
35.

Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity.

Haslanger MF, Sybertz EJ, Neustadt BR, Smith EM, Nechuta TL, Berger J.

J Med Chem. 1989 Apr;32(4):737-9. No abstract available.

PMID:
2522989
36.

Effects of BRL 34915, a putative K channel opener, on transmembrane 45Ca movements in rabbit aortic smooth muscle.

Chiu PJ, Tetzloff G, Ahn HS, Sybertz EJ.

Eur J Pharmacol. 1988 Oct 18;155(3):229-37.

PMID:
3234486
37.

Phorbol 12,13-dibutyrate, an activator of protein kinase C, stimulates both contraction and Ca2+ fluxes in dog saphenous vein.

Chiu PJ, Tetzloff G, Chatterjee M, Sybertz EJ.

Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):114-20.

PMID:
3185741
38.

Effects of the antihypertensive dilevalol on aortic compliance in anesthetized dogs.

Watkins RW, Sybertz EJ, Antonellis A, Pula K, Rivelli M.

J Cardiovasc Pharmacol. 1988 Jul;12(1):42-50.

PMID:
2459533
39.

Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta.

Chiu PJ, Tetzloff G, Ahn HS, Sybertz EJ.

Am J Hypertens. 1988 Jul;1(3 Pt 1):262-8.

PMID:
2455529
40.

Comparative effects of verapamil, diltiazem and nifedipine on aortic compliance in anesthetized dogs.

Watkins RW, Sybertz EJ, Pula K, Antonellis A.

Arch Int Pharmacodyn Ther. 1988 May-Jun;293:134-42.

PMID:
3421772
41.

Synthesis and pharmacological activity of angiotensin converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines.

Smith EM, Swiss GF, Neustadt BR, Gold EH, Sommer JA, Brown AD, Chiu PJ, Moran R, Sybertz EJ, Baum T.

J Med Chem. 1988 Apr;31(4):875-85.

PMID:
2832605
42.

Effect of amiloride on regulatory mechanisms of vascular smooth muscle contraction.

Chatterjee M, Chiu PJ, Doll RJ, Sybertz EJ.

Biochem Pharmacol. 1988 Mar 1;37(5):813-8.

PMID:
2449893
43.

Effects of spiraprilic acid, an angiotensin converting enzyme inhibitor, on large artery compliance in anesthetized dogs.

Watkins RW, Sybertz EJ, Antonellis A, Pula K.

Arch Int Pharmacodyn Ther. 1987 Dec;290(2):222-34.

PMID:
2833190
44.

The responses of atrial natriuretic factor concentrations to acute volume changes in conscious rats.

Chiu PJ, Vemulapalli S, Policelli M, Kifor I, Sybertz EJ, Dzau VJ.

Life Sci. 1987 Nov 23;41(21):2339-47.

PMID:
2960866
45.

Nitroprusside, but not ANF inhibits venoconstriction in an in situ rat model.

Watkins RW, Sybertz EJ, Tedesco RP.

Eur J Pharmacol. 1987 Nov 17;143(3):299-304.

PMID:
2961584
46.

Comparative renal effects of calcium channel blockers in conscious spontaneously hypertensive rats.

Vemulapalli S, Chiu PJ, Sybertz EJ.

Arch Int Pharmacodyn Ther. 1987 Jun;287(2):309-22.

PMID:
2888444
47.

Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.

Sybertz EJ, Baum T, Ahn HS, Desiderio DM, Pula KK, Tedesco R, Washington P, Sabin C, Smith E, Becker F, et al.

Arch Int Pharmacodyn Ther. 1987 Apr;286(2):216-29.

PMID:
3036028
48.

Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).

Baum T, Watkins RW, Sybertz EJ, Ahn HS, Nelson S, Coleman W, Tedesco R, Pula KK, Rivelli M, Sabin C.

Arch Int Pharmacodyn Ther. 1987 Apr;286(2):230-45.

PMID:
2884941
49.

Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor.

Sybertz EJ, Watkins RW, Ahn HS, Baum T, La Rocca P, Patrick J, Leitz F.

J Cardiovasc Pharmacol. 1987;10 Suppl 7:S105-8.

PMID:
2485040
50.

Effects of the antihypertensive dilevalol on large artery compliance in anesthetized dogs.

Watkins RW, Sybertz EJ, Antonellis A, Pula K, Rivelli M.

J Cardiovasc Pharmacol. 1987;10 Suppl 11:S58-63.

PMID:
2454369

Supplemental Content

Loading ...
Support Center